Endocrine Abstracts

Objectives: To describe the prevalence of liver steatosis in a cohort of patients with Cushing’s disease.Methods: Cross-sectional descriptive study. We included 59 patients with Cushing’s disease from our cohort of patients who underwent a Fibroscan to analyze the degree of hepatic steatosis (CAP measured in dB/m) and liver fibrosis (fibrosis measured in kPa). Biochemical algorithms of liver steatosis and fibrosis were assessed.<p class="ab...

Introduction: Endoscopic transsphenoidal pituitary surgery has become the first line method for removal pituitary tumours. A new way to see the surgical field and the cooperation of two neurosurgeons has supposed a revolution in the area.Objetives: Analyse surgical outcomes and complications of a cohort of patients from a single center who underwent ETPS for Cushing disease.Methods: Descriptive prospective-retrospective study inclu...

Introduction: Pituitary abscess (PA) is a rare condition, representing less than 1% of pituitary lessions. Only around 200 cases have been reported in the scientific literature. Preoperative diagnosis is often challenging due to nonspecific clinical and radiological manifestations.Materials and methods: Retrospective descriptive cohort study. We analyze demographic and clinical variables, hormonal involvement, recurrence, type of surgery and antibiotic t...

Methods: Descriptive retrospective study among patients who underwent ETPS for ACTH-secreting pituitary adenomas performed by the same surgical team from January/2013 to January/2017.Results: 27 ACTH-secreting pituitary adenomas operated via ETPS. 20 (74.1%) were women, median age at surgery was 43.25 [29.65–61.59] years and median follow-up was 3.13 [1.6–6.69] years. Presurgically, 25 (92.59%) patients recieved drugs for control cortisol hyper...

Methods: We conducted a retrospective descriptive study including 67 patients with non-functioning pituitary adenomas surgicaly removed via ETPS beetwen January/2013 to January/2017.Results: Among 67 patients with non-functioning pituitary adenomas surgicaly removed via ETPS 44 (65.67%) were men. 52 (77.61%) patients recieved their first surgery, 14 (20.9%) had been operated one time before and 1 (1.49%) had been operated two times. Every patient reopera...

Objectives: The transition from the paediatric age to the adult is a particularly vulnerable period in patients with metabolic congenital diseases (mcd). In andalusia two adults’ units exist (seville and malaga) for the follow-up of these patients. Our aim in this study was to evaluate the current series of attended patients.Material and methods: We evaluated all patients transferred to the adult units since 2008. The clinical records were analyzed ...

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...

Pituitary adenomas are heterogeneous, rare tumors, which hinders analysis of large numbers of cases with common approaches. To overcome this, a multicenter, clinical-basic strategy was proposed aimed at enhancing the tools to diagnose and manage pituitary tumors by combining clinical/pathological/molecular information. This initiative was developed by the Sociedad Andaluza de Endocrinología y Nutrición, and further endorsed by the Sociedad Española de Endocrinol...

Introduction: ACROCOMB is a retrospective Spanish Multicenter study, designed to evaluate the efficacy (extent of tumour control) and safety of lanreotide (LAN) treatment combined with pegvisomant (PEG) or cabergoline in acromegalic patients with monotherapy failure.Methods: patients with acromegaly treated with LAN+PEG (45% of ACROCOMB patients) at 44 Spanish Endocrinology Departments were analysed.Results: 40% of patients were ma...

IntroductionCushing’s disease is the result of prolonged exposure to excess cortisol caused by a pituitary tumor, known as corticotropinoma, which hypersecretes adrenocorticotropin (ACTH). Treatment with somatostatin analogs (SSA) has been shown to reduce hormone secretion and, to a lower extent, tumor growth in some subtypes of pituitary tumors, such as growth hormone secreting tumors. However, SSA are commonly ineffective in corticotropinomas. Pre...